Bristol-myers Squibb Compnay

Other

Min Ding

Robert G Gentles

Piyasena Hewawasam

Xiaofan Zheng

Scott W Martin

John A Bender

Louis Stanley Chupak

John F Kadow

Thomas W Hudyma

Kap-Sun Yeung

Yazhong Huang

Richard Eric Olson

Upender Velaparthi

Jayakumar Sankara Warrier

Carl P Bergstrom

Prasada Rao Jalagam

Saumya Roy

Nicholas A Meanwell

John S Tokarski

John E Starrett, Jr

Ivar M McDonald

Katharine A Grant-Young

Ying Han

Yong Tu

Bireshwar Dasgupta

Chetan Padmakar Darne

Hasibur Rahaman

Gopikishan Tonukunuru

Manjunatha Narayana Rao Kamble

Raju Mannoori

Sivasudar Velaiah

Kotha Rathnakar Reddy

Thiruvenkadam Raja

Paul Michael Scola

Feng He

Shuanghua Hu

John E Macor

Makonen Belema

David R Langley

Lawrence B Snyder

Li-Qiang Sun

Joanne J Bronson

Michael H Serrano-Wu

Omar D Lopez

Xi Chen

Denis R St Laurent

Van N Nguyen

Yuping Qiu

Timothy P Connolly

Lawrence R Marcin

Zhong Yang

Stephen E Mercer

F Christopher Zusi

Ningning Xu

Mendi A Higgins

Juliang Zhu

Ivar M Mcdonald

Daniel J Tenney

Denise Christine Grunenfelder

Michael Wichroski

Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CRor N; Y is CRor N; R, R, R, R, R, R, R, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Substituted bicyclic compounds useful as T cell activators

Disclosed are compounds of Formula (I): or a salt thereof, wherein: R, R, R, and Rare defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK α) and diacylglycerol kinase zeta (DGKζ), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Naphthyridinone compounds useful as T cell activators

Disclosed are compounds of Formula (I): or a salt thereof, wherein: R, R, R, R, R, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK&#x3b1;) and diacylglycerol kinase zeta (DGK&#x3b6;), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

Substituted naphthyridinone compounds useful as T cell activators

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

Compounds useful as immunomodulators

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds modulate the mGluR2 receptor and may be useful for the treatment of various disorders of the central nervous system. 

Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders

The present disclosure is generally directed to compounds that can inhibit DAGL&#x3b1; and/or &#x3b2; activity, compositions comprising such compounds, and methods for inhibiting DAGL&#x3b1; and/or &#x3b2; activity.

Glycine chroman-6-sulfonamides for use as inhibitors of diacylglycerol lipase

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C virus inhibitors

The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the treatment of hepatitis C

The present disclosure relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

The invention encompasses compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Compounds for the treatment of Hepatitis C

Growing community of inventors

Glastonbury, CT, United States of America

Min Ding